Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressants.
The gradual onset of action and pronounced pharmacokinetic variability provide a solid rationale for drug plasma level monitoring in psychopharmacology. For tricyclic antidepressants a well-established drug level therapeutic effect relationship is available for a few compounds (imipramine, nortiptyline, amitriptyline); and for these, plasma level monitoring can ensure more efficient and safe treatment. The relationship has been demonstrated only in endogenously depressed patients. Various pharmacokinetic problems such as dose-dependent kinetics (imipramine in elderly patients), autoinduction (chlorpromazine), drug interaction (inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants), and changes in protein binding may be better controlled by monitoring the drug levels. In amitriptyline intoxications, a possible change in the elimination kinetics results in a very slow decline in plasma levels for several days; and plasma level measurements might help to identify those patients at prolonged risk of adverse reactions. Some side effects--in particular, orthostatic hypotension--occur at subtherapeutic drug levels and therefore cannot be prevented by drug level monitoring, and monitoring of other (physiological) variables is more important. Drug level monitoring of tricyclic antidepressants thus can be considered a valuable addition to the treatment program, but it cannot replace proper clinical practice in terms of diagnostic evaluation and control of patients.
D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D001711:Biotransformation; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D011619:Psychotropic Drugs / Q000097:blood*; D012463:Saliva / Q000032:analysis
D000929:Antidepressive Agents, Tricyclic; D011619:Psychotropic Drugs